Target detection: Magnetic resonance imaging-ultrasound fusion-guided prostate biopsy Review uri icon

Overview

MeSH Major

  • Image-Guided Biopsy
  • Magnetic Resonance Imaging
  • Prostate
  • Prostatic Neoplasms
  • Ultrasonography, Interventional

abstract

  • Recent advances in multiparametric magnetic resonance imaging (MRI) have enabled image-guided detection of prostate cancer. Fusion of MRI with real-time ultrasound (US) allows the information from MRI to be used to direct biopsy needles under US guidance in an office-based procedure. Fusion can be performed either cognitively or electronically, using a fusion device. Fusion devices allow superimposition (coregistration) of stored MRI images on real-time US images; areas of suspicion found on MRI can then serve as targets during US-guided biopsy. Currently available fusion devices use a variety of technologies to perform coregistration: robotic tracking via a mechanical arm with built-in encoders (Artemis/Eigen, BioJet/Geoscan); electromagnetic tracking (UroNav/Philips-Invivo, Hi-RVS/Hitachi); or tracking with a 3D US probe (Urostation/Koelis). Targeted fusion biopsy has been shown to identify more clinically significant cancers and fewer insignificant cancers than conventional biopsy. Fusion biopsy appears to be a major advancement over conventional biopsy because it allows (1) direct targeting of suspicious areas not seen on US and (2) follow-up biopsy of specific cancerous sites in men undergoing active surveillance.

publication date

  • January 2014

Research

keywords

  • Review

Identity

Language

  • eng

PubMed Central ID

  • PMC4019721

Digital Object Identifier (DOI)

  • 10.1016/j.urolonc.2013.08.006

PubMed ID

  • 24239473

Additional Document Info

start page

  • 903

end page

  • 11

volume

  • 32

number

  • 6